Gossamer Bio has structured the financing around key seralutinib regulatory milestones, with $150 million committed and another $100 million potentially available if the pulmonary arterial hypertension drug receives FDA approval.
Key Investor Takeaways
- Gossamer Bio (NASDAQ:GOSS) has secured up to $250 million through a structured private placement tied to seralutinib’s regulatory progress.
- The financing includes $150 million of committed capital: approximately $25 million upfront and $125 million contingent on FDA acceptance of the PAH new drug application in 2026.
- A further $100 million could be raised through warrants exercisable following potential FDA approval of seralutinib.
- Gossamer expects the initial and committed second-closing proceeds, combined with existing resources, to fund operations into 2028.
- The financing comes ahead of the planned September 2026 seralutinib NDA submission and follows the company’s reacquisition of worldwide rights to the drug.
Why GOSS Stock Is in Focus
Gossamer Bio has entered into a securities purchase agreement with new and existing institutional investors for a private placement capable of generating approximately $250 million in gross proceeds.
The first approximately $25 million is expected to fund at an initial closing around August 24, 2026. Investors will purchase pre-funded warrants at $0.1399 each, equivalent to a $0.14 common stock price less the $0.0001 warrant exercise price.
A substantially larger $125 million second closing is tied to FDA acceptance of Gossamer’s seralutinib NDA for pulmonary arterial hypertension. The milestone must occur during 2026, alongside satisfaction of customary conditions, for investors to be obligated to provide the capital.
At that second closing, investors will also receive FDA Approval Warrants. Full cash exercise at $0.187 per share following FDA approval could generate another approximately $100 million.
The investor group includes EcoR1 Capital, 683 Capital Partners, RA Capital Management, Coastlands Capital, Samsara BioCapital and Rock Springs Capital, among others.
Why This Matters for Investors
The structured private placement directly links Gossamer Bio’s funding position to seralutinib’s regulatory pathway.
With the NDA submission planned for September, FDA acceptance represents both a regulatory milestone and the trigger for approximately $125 million of additional committed financing. If that milestone occurs during 2026, Gossamer expects to receive the entire $150 million committed under the transaction this year.
That structure may reduce near-term funding uncertainty around the planned NDA review. Gossamer said the initial and second-closing proceeds, together with its existing cash, cash equivalents and marketable securities, are expected to fund operations into 2028.
The potential additional $100 million creates another source of capital if seralutinib reaches FDA approval, although that funding is not committed and depends on investors exercising the warrants for cash.
The financing also comes after Gossamer reacquired worldwide rights to seralutinib. As a result, the company is positioning its capital base to support not only clinical development but also potential commercialization in PAH and continued development in PH-ILD.
For investors, this shifts attention toward regulatory execution. The financing provides a defined pathway to additional capital, but access to most of the announced $250 million remains dependent on seralutinib reaching specific FDA milestones.
What to Watch Next
The planned September 2026 seralutinib NDA submission is the immediate catalyst, followed by whether the FDA accepts the application before year-end and triggers the approximately $125 million second closing.
Investors can also watch for the special stockholder meeting required for approval under Nasdaq listing rules, subsequent regulatory developments for seralutinib in PAH and, ultimately, whether FDA approval activates the warrants capable of providing another approximately $100 million.